Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.62 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.62 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975582 | 0.95 | SIRT2 (0.58) | SIRT2SIRT1SIRT3TGM2HTT | |
| SCHEMBL9975581 | 0.95 | SIRT2 (0.58) | SIRT2SIRT1SIRT3TGM2HTT | |
| SCHEMBL9975659 | 0.92 | CTSL (0.56) | SIRT2SIRT1SIRT3TGM2HTT | |
| SCHEMBL10659971 | 0.92 | HTT (0.68) | SIRT2SIRT1SIRT3TGM2HTT | |
| SCHEMBL16692630 | 0.92 | HTT (0.68) | SIRT2SIRT1SIRT3TGM2HTT | |
| SCHEMBL28969063 | 0.92 | HTT (0.68) | SIRT2SIRT1SIRT3TGM2HTT | |
| SCHEMBL11973884 | 0.92 | HTT (0.68) | SIRT2SIRT1SIRT3TGM2HTT | |
| SCHEMBL3364812 | 0.92 | HTT (0.68) | SIRT2SIRT1SIRT3TGM2HTT | |
| SCHEMBL10599151 | 0.92 | HTT (0.68) | SIRT2SIRT1SIRT3TGM2HTT | |
| SCHEMBL9975576 | 0.91 | SIRT2 (0.56) | SIRT2SIRT1SIRT3TGM2DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450385-B2 | Urea-urethane gellant compositions with controlled molecular weight and methods of preparation | XEROX CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120157562-A1 | UREA-URETHANE GELLANT COMPOSITIONS WITH CONTROLLED MOLECULAR WEIGHT AND METHODS OF PREPARATION | XEROX CORPORATION (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157562-A1 | UREA-URETHANE GELLANT COMPOSITIONS WITH CONTROLLED MOLECULAR WEIGHT AND METHODS OF PREPARATION | UGP2, PUF60, UBA7 | SIRT2 2814/4885SIRT1 2278/4885SIRT3 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.